Johnson & Johnson (JNJ)

JNJ (NYSE:Drugs) EQUITY
$114.15
pos +0.00
+0.00%
Today's Range: 114.08 - 115.03 | JNJ Avg Daily Volume: 7,070,000
Last Update: 01/20/17 - 4:00 PM EST
Volume: 0
YTD Performance: -0.92%
Open: $0.00
Previous Close: $114.20
52 Week Range: $95.95 - $126.07
Oustanding Shares: 2,720,531,728
Market Cap: 310,684,723,338
6-Month Chart
TheStreet Ratings Grade for JNJ
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 8 8 8
Moderate Buy 2 2 2 2
Hold 9 8 8 7
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.26 2.16 2.16 2.11
Latest Dividend: 0.80
Latest Dividend Yield: 2.80%
Dividend Ex-Date: 02/24/17
Price Earnings Ratio: 20.04
Price Earnings Comparisons:
JNJ Sector Avg. S&P 500
20.04 20.20 0.00
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-0.63% 19.22% 20.08%
GROWTH 12 Mo 3 Yr CAGR
Revenue -5.70 0.00 0.01
Net Income -5.60 0.50 0.13
EPS -3.90 0.40 0.12
Earnings for JNJ:
EBITDA 22.04B
Revenue 70.07B
Average Earnings Estimates
Qtr (12/16) Qtr (03/17) FY (12/16) FY (12/17)
Average Estimate $1.56 $1.75 $6.71 $7.06
Number of Analysts 12 6 12 13
High Estimate $1.62 $1.79 $6.75 $7.25
Low Estimate $1.54 $1.67 $6.69 $6.83
Prior Year $1.44 $1.68 $6.20 $6.71
Growth Rate (Year over Year) 8.04% 3.97% 8.17% 5.27%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
RMPIA
By

Doug Kass

 | Jan 19, 2017 | 4:13 PM EST
The U.S. dollar weakened. The price of crude oil rose by about two bits to $51.40. Gold fell by $8 to $1,203. I am buyer, to replace the half position I sold soon. Ag commodities: wheat down $0.08, corn up $0.02, soybean down $0.05 and oats up $0.01. Lumber was flat. For the second day in a row bonds got schmeissed iShares Barclays 20+ Yr Treas.Bond ETF (TLT) down over a beaner, again. (Good sale in fixed income last week!) The 10-year bond yield rose by 7 basis points to 2.46%. The long bond yield rose by 5 basis points. The 2s/10s expanded by 4 basis points to about 124 basis points. Municipals got hit and so did closed-end muni-bond funds. High yield was junky - but Blackstone / GSO Strategic Credit Fund (BGB) rose by a penny. Banks continue to be sold for a second day in a row -- despite much higher bond yields and lower bond prices. Crickets from financial bulls -- who seem to rationalize the large move this week and lack of correlation to bonds as a random act. Our "Trade of the Week" (short C) is now down by 5.5% or $3 since the trade was discussed in my Diary. Retail remains for sale. But my view is that a sentiment extreme is developing. Insurance stocks got whacked, including fav Hartford Financial (HIG) . Brokerages got hit, too. Goldman Sachs (GS) , put on Best Ideas List last week at $242, is down to $231. Biotech was lower, but not materially so (Celgene (CELG)Allergan (AGN) lower). Hwwever, spec biotech roiled to the downside (Intrexon (XON) , Ziopharm Oncology (ZIOP) , Acadia Pharmaceuticals (ACAD) , Aerie Pharmaceuticals (AERI) ). Autos mixed. Ford (F) up, General Motors (GM) down. Good for our
By

Skip Raschke

 | Jan 18, 2017 | 8:00 AM EST
After an up-and-down year, this household name is as strong as ever.
RMPIA
By

Bret Jensen

 | Jan 17, 2017 | 11:00 AM EST
Deals already are popping up, and we'll soon have earnings reports from the industry giants.
RMPIA
By

Bret Jensen

 | Jan 10, 2017 | 10:00 AM EST
Animal health and oncology deal activity is heating up in 2017.
RMPIA
By

David Katz

 | Jan 8, 2017 | 2:00 PM EST
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
RMPIA
By

Jim Cramer

 | Jan 6, 2017 | 3:10 PM EST
Disney and Goldman are doing a lot of the heavy lifting.
RMPIA
By

David Katz

 | Jan 6, 2017 | 7:00 AM EST
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
By

Jim Cramer

 | Dec 22, 2016 | 11:32 AM EST
Jim Cramer wonders whether someone at Johnson & Johnson is now willing to pay more for Actelion, or if there was more give from the other side.
By

Tim Hesselsweet

 | Dec 16, 2016 | 11:48 AM EST
The Fed seems to have aligned itself with the new emerging themes of financials and small-caps.
By

Jim Cramer

 | Dec 14, 2016 | 12:12 PM EST
Jim Cramer comments on Johnson & Johnson's move to abandon merger talks with Actelion.

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.